Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. Pfizer's financial ...

If you're holding shares of Vertex Pharmaceuticals or thinking about adding some to your portfolio, you're not alone in wondering what the right move is. The stock's recent momentum may have caught ...

Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals but can be extremely addictive. Vertex broke those barriers with Journavx, ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Vertex gets EU okay to treat younger cystic fibrosis patients A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to children as young as six if they have ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex ...

President Donald Trump's policy of attacks on vessels he says are linked to the drug trade and the regime of Venezuelan President Nicolas Maduro could lead to the U.S. leader ordering air strikes on ...

Republicans are ratcheting up pressure on Democrats on multiple fronts as the government shutdown enters a third workweek, hoping hardball moves can force a reckoning that cracks the stalemate. The ...

ASML Holding NV said demand for its most sophisticated chip-making machines is soaring thanks to the artificial intelligence boom, signaling optimism just months after the semiconductor equipment ...

Anthropic projects as much as $26 billion in annualized revenue in 2026 Anthropic projects $9 billion in annualized revenue by end of 2025 Enterprise customers drive 80% of Anthropic's revenue Oct 15 ...